News & Events

Redbiotec announces today the appointment of Research Associate Professor Sita Awasthi from the University of Pennsylvania,Infectious Disease Division, Perelman School of Medicine, to its team. Sita Awasthi is a leading expert in vaccine development and immunology of infectious diseases, and will support Redbiotec in its Herpes Simplex Virus vaccine program.

Redbiotec has filed a new patent application covering its novel antigens against Herpes simplex viruses. The antigens developed by Redbiotec comprise potent trimers and dimers as well as combinations thereof. Redbiotec expects first results from its ongoing in vitro and in vivo studies by Q2 2016.

Redbiotec will attend JPM 34th Healthcare Conference in San Francisco starting January 11 2016. Redbiotec’s delegation will include the two projects leaders of Redbiotec’s HSV-2 vaccine and Universal Flu vaccine programs.

Redbiotec announces today the appointment of Professor & Director Lbachir BenMohamed from UC Irvine, School of Medicine, to Redbiotec’s team. Professor BenMohamed is a leading expert in immunology and in particular in the field of the Herpes Simplex Virus HSV.

The announcement on January 5th of the acquisition of Redvax, spin-off of Redbiotec, by Pfizer was covered by a large number of news outlets worldwide, including Financial Times, Walls Street Journal, Nasdaq, NZZ.

Redbiotec would like to thank for the positive global feedback from CMV experts, life science investors, business developers, financial advisors and entrepreneurs we received last week.

Please also read Redbiotec press release.